2-chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent langerhans cell histiocytosis (LCH) in pediatric patients

Medical and Pediatric Oncology

Volumn 29, Issue 4, 1997, Pages 288-292

  Stine, K C ^a   Saylors, R L ^a   Williams, L L ^a   Becton, D L ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

2 chlorodeoxyadenosine (2 CDA); Langerhans cell histiocytosis (LCH); Pediatrics

Indexed keywords

CLADRIBINE; CYCLOSPORIN; ETOPOSIDE; PREDNISONE; VINBLASTINE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTIOCYTOSIS X; HUMAN; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT PLANNING;

ADOLESCENT; CHILD, PRESCHOOL; CLADRIBINE; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROSPECTIVE STUDIES; RECURRENCE; SKULL;

EID: 0030795349     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199710)29:4<288::AID-MPO9>3.0.CO;2-I     Document Type: Article

References (17)